J
Jing Lu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 25
Citations - 2815
Jing Lu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 13, co-authored 21 publications receiving 2316 citations. Previous affiliations of Jing Lu include Novartis & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu,Yimin Qian,Martha Altieri,Hanqing Dong,Jing Wang,Kanak Raina,John Hines,James D. Winkler,Andrew P. Crew,Kevin Coleman,Craig M. Crews +10 more
TL;DR: ARV-825 is designed, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation ofBRD4 in all BL cell lines tested.
Journal ArticleDOI
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Kanak Raina,Jing Lu,Yimin Qian,Martha Altieri,Deborah M. Gordon,Ann Marie Rossi,Jing Wang,Xin Chen,Hanqing Dong,Kam W. Siu,James D. Winkler,Andrew P. Crew,Craig M. Crews,Kevin Coleman +13 more
TL;DR: This study proves that ARV-771, a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.
Journal ArticleDOI
Breast Cancer Metastasis: Challenges and Opportunities
Jing Lu,Patricia S. Steeg,Janet E. Price,Savitri Krishnamurthy,Sendurai A. Mani,James M. Reuben,Massimo Cristofanilli,Gabriela Dontu,Luc Bidaut,V. Valero,Gabriel N. Hortobagyi,Dihua Yu +11 more
TL;DR: Despite exciting progress in the understanding of breast cancer development and progression, and in the development of novel therapeutic strategies, breast cancer remains the second leading cause of cancer-related death in women.
Journal ArticleDOI
14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition
Jing Lu,Hua Guo,Warapen Treekitkarnmongkol,Ping Li,Jian Zhang,Bin Shi,Chen Ling,Xiaoyan Zhou,Tongzhen Chen,Paul J. Chiao,Xinhua Feng,Victoria L. Seewaldt,William J. Muller,Aysegul A. Sahin,Mien Chie Hung,Mien Chie Hung,Dihua Yu +16 more
TL;DR: Patients whose breast tumors overexpressed both ErbB2 and 14-3-3zeta had higher rates of metastatic recurrence and death than those whose tumors overexpressed only one.
Journal ArticleDOI
14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival
Christopher L. Neal,Jun Yao,Wentao Yang,Wentao Yang,Xiaoyan Zhou,Nina T. Nguyen,Jing Lu,Christopher G. Danes,Hua Guo,Keng-Hsueh Lan,Keng-Hsueh Lan,Joe Ensor,Walter N. Hittelman,Mien Chie Hung,Dihua Yu +14 more
TL;DR: It is shown that 14-3-3zeta overexpression also persisted in invasive ductal carcinoma and contributed to the further progression of breast cancer and may serve as an effective therapeutic target in patients whose tumors overexpress 14- 3- 3zeta.